Reig Jofre (BME:RJF) Margin Compression To 1.5% Tests Bullish Earnings Narratives

Laboratorio Reig Jofre (BME:RJF) has just wrapped up FY 2025 with fourth quarter revenue of €94.7m and net income of €3.1m, translating to Basic EPS of €0.04. The trailing 12 month figures show revenue of €336.7m and net income of €5.0m, with Basic EPS of €0.06. Over recent quarters, revenue has ranged from €72.8m to €94.7m, and quarterly net income has moved between a loss of €2.1m and a profit of €3.7m. This sets up a picture where investors are likely to focus on how consistent margins really are beneath the headline EPS.

See our full analysis for Laboratorio Reig Jofre.

With the latest results on the table, the next step is to see how these numbers line up with the widely shared narratives around Reig Jofre's growth potential and earnings quality, and where the data challenges those stories.

See what the community is saying about Laboratorio Reig Jofre

Margins squeezed, net profit margin at 1.5%

• Across the last 12 months, Reig Jofre converted €336.7m of revenue into €5.0m of net income, which works out to a 1.5% net profit margin compared with 3% a year earlier.
• Critics highlight that a 1.5% margin and a one off €1.8m loss leave little cushion, and that view is partly backed by the numbers,
  • In FY 2025, quarterly net income swung from a €2.1m loss in Q2 to a €3.7m profit in Q1, showing that profitability has been quite sensitive to cost or one off items.
  • The one off €1.8m loss directly reduced trailing net income from what it would have been otherwise, so anyone focused on margin pressure needs to separate that effect from the underlying run rate.

Revenue steady, but earnings volatility stands out

• Over FY 2025, quarterly revenue stayed within a relatively tight band between €72.8m and €94.7m, while net income moved between a €2.1m loss and a €3.7m profit, underlining that earnings moved around more than sales.
• What is striking for a bullish story that leans on earnings growth is how stable revenue compares with the lumpier profit line,
  • On a trailing basis, revenue hovered in a range of about €330.3m to €342.9m, yet trailing net income over the same snapshots went from €10.8m at the start of the period to €5.0m most recently.
  • The bullish angle that earnings can compound over time sits alongside this record of swings, which means any improvement case has to pass the simple test of matching or beating past peaks in net income, not just holding revenue.

Rich 45.1x P/E and DCF fair value of €2.11

• The stock trades on a trailing P/E of 45.1x compared with 20.9x for the wider European Pharmaceuticals group and 40.8x for peers, while the current share price of €2.78 sits above a DCF fair value of about €2.11.
• For a more cautious, bearish take, the gap between price and fundamentals is where attention usually lands,
  • The current P/E of 45.1x is above both the broader European industry average and peer average, so the stock is priced more expensively than many sector alternatives based on trailing earnings.
  • At the same time, the DCF fair value of about €2.11 is below the €2.78 share price, so anyone worried about overpaying can point to both the higher multiple and the modelled cash flow value when arguing the stock already bakes in a lot of optimism.

Skeptical investors who see the 45.1x P/E and DCF fair value of €2.11 as red flags may want to read a deeper breakdown of the cautious case before deciding how much risk to take on here 🐻 Laboratorio Reig Jofre Bear Case.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Laboratorio Reig Jofre on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With sentiment split between cautious and optimistic views, it helps to look at the underlying data yourself and decide how comfortable you are with the balance between risks and potential rewards, especially if you want to move quickly and shape your own view using the 2 key rewards and 2 important warning signs.

Explore Alternatives

Reig Jofre combines thin 1.5% net margins, volatile earnings and a 45.1x P/E that sits above its sector averages and DCF fair value estimate.

If that mix of tight profitability and a rich earnings multiple makes you uneasy, compare it with companies that screen as potentially better priced using the 227 high quality undervalued stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com